Skip to main content

Inverness Throws Down Gauntlet Again, Raises Bid for Biosite to $92.50 Per Share

NEW YORK (GenomeWeb News) - Biosite said today that it has received a revised merger offer from Inverness Medical Innovations of $92.50 per share, up from Inverness’ original offer of $90 per share.
The newest development in the proposed takeover of Biosite comes one week after Beckman Coulter matched Inverness’ $90 per-share bid.
Beckman had initially bid $85 per share for Biosite in late March.
Biosite said it is evaluating Inverness’ offer, which expires at 8 a.m. EDT, May 16. Inverness reserves the right to withdraw the offer, however, if, among other things, Biosite does not publicly state by the end of the business day today that Inverness' bid is superior to Beckman’s most recent offer.
Inverness also wants Biosite to stipulate that Beckman has until 11:59 PM EDT, May 15 to match its offer.
Beckman officials could not be reached for comment by press time.
The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.